会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 81. 发明申请
    • MODIFYING A COSMETIC PRODUCT BASED ON A MICROBE PROFILE
    • 基于MICROBE配置文件修改化妆品
    • US20150057940A1
    • 2015-02-26
    • US14294508
    • 2014-06-03
    • Elwha LLC
    • Michael H. BaymRoderick A. HydeJordin T. KareEric C. LeuthardtGary L. McKnightTony S. PanElizabeth A. SweeneyClarence T. TegreeneLowell L. Wood, JR.
    • G06F19/00
    • G06F19/704
    • Systems and methods are described for modifying a cosmetic product based on a microbe profile including an ingredient-microbe interaction dataset including information associated with interactions between reference cosmetic ingredients and types of reference microbes; and a computing device including circuitry configured to receive information associated with the microbe profile of an individual, receive information associated with an ingredient list of the cosmetic product, compare the microbe profile of the individual and the ingredient list of the cosmetic product to the ingredient-microbe interaction dataset, identify an interaction between at least one cosmetic ingredient in the ingredient list of the cosmetic product and at least one of the one or more types of microbes in the microbe profile of the individual, recommend a modification to the ingredient list in response to an identified interaction, and report to a user the recommended modification.
    • 描述了用于基于包括成分 - 微生物相互作用数据集在内的微生物分布修饰化妆品的系统和方法,所述成分 - 微生物相互作用数据集包括与参考化妆品成分与参考微生物类型之间的相互作用相关的信息; 以及计算设备,其包括被配置为接收与个体的微生物谱相关联的信息的电路,接收与化妆品的成分列表相关联的信息,将所述个体的微生物谱和所述化妆品的成分列表与成分 - 微生物相互作用数据集,鉴定化妆品的成分列表中的至少一种化妆品成分与个体的微生物概况中的一种或多种类型的微生物中的至少一种之间的相互作用,推荐对成分列表进行响应 到一个识别的交互,并向用户报告推荐的修改。
    • 84. 发明申请
    • System and Method for Automated Determination of the Relative Effectiveness of Anti-Cancer Drug Candidates
    • 自动测定抗癌药物候选药物相对效力的系统和方法
    • US20140141462A1
    • 2014-05-22
    • US13803623
    • 2013-03-14
    • DiaTech Oncology
    • Mathieu PerreeAllan E. HallquistOlivier Petit
    • G01N33/50
    • G01N33/5011G01N33/5044G06F19/704G06F19/709
    • A computer system is provided for determining the relative effectiveness of anti-cancer drugs. The interface has selectable options, including an option to manage drug testing parameters, and enables user selection of desired drug testing parameters in relation to a virtual well plate associated with a physical well plate of a spectrophotometer. The computer system causes the spectrophotometer to start a drug test, wherein the physical well plate includes at least one test well containing viable cancer cells; and at least one drug candidate in a predetermined concentration; and at least one control well containing the viable cancer cells alone. The system records the optical density of the well at a predetermined wavelength at selected time intervals for a selected duration of time, and stores the optical density and time measurements in the database. An activity value is calculated from the optical density and time measurements, and a correlation is displayed between the activity value and the drug candidate's ability to induce apoptosis in the cancer cells.
    • 提供了一种计算机系统来确定抗癌药物的相对有效性。 该界面具有可选择的选项,包括管理药物测试参数的选项,并且使用户可以选择相关于与分光光度计的物理井板相关联的虚拟井板所需的药物测试参数。 计算机系统使得分光光度计开始药物测试,其中物理井板包括至少一个含有活的癌细胞的测试孔; 和至少一种预定浓度的候选药物; 以及含有单独存活的癌细胞的至少一个对照孔。 该系统以选定的时间间隔将预定波长的阱的光密度记录在选定的时间内,并将光密度和时间测量值存储在数据库中。 从光密度和时间测量计算活性值,并且在活性值和药物候选物诱导癌细胞凋亡的能力之间显示相关性。
    • 85. 发明申请
    • SYSTEMS AND METHODS FOR CHARACTERIZATION OF MOLECULES
    • 用于表征分子的系统和方法
    • US20140065642A1
    • 2014-03-06
    • US14049249
    • 2013-10-09
    • Analiza, Inc.
    • Arnon ChaitBoris Y. Zaslavsky
    • G01N33/543
    • G01N33/57434G01N33/53G01N33/543G01N33/68G01N33/6803G01N33/6842G01N33/6845G01N2333/96441G01N2333/96455G06F19/00G06F19/12G06F19/18G06F19/704G16H50/50
    • The present invention generally provides systems and methods for the detection, identification, or characterization of differences between properties or behavior of corresponding species in two or more mixtures comprised of molecules, including biomolecules and/or molecules able to interact with biomolecules, using techniques such as partitioning. The experimental conditions established as distinguishing between the mixtures of the molecules using the systems and methods of the invention can also be used, in some cases, for further fractionation and/or characterization of the biomolecules and/or other molecules, using techniques such as single-step or multiple-step extraction, and/or by liquid-liquid partition chromatography. The methods could also be used for discovering and identifying markers associated with specific diagnostics, and can be used for screening for such markers once discovered and identified during diagnostics screening.
    • 本发明通常提供用于检测,鉴定或表征两种或更多种由分子组成的混合物的性质或行为之间的差异的系统和方法,包括生物分子和/或能够与生物分子相互作用的分子,使用诸如 分区 使用本发明的系统和方法区分分子的混合物所建立的实验条件也可以在某些情况下用于进一步分级和/或表征生物分子和/或其他分子,使用诸如单一 - 步骤或多步萃取,和/或通过液 - 液分配色谱法。 该方法还可用于发现和识别与特定诊断相关的标记,并且可以在诊断筛选期间发现和鉴定后用于筛选此类标记物。
    • 90. 发明授权
    • Method for simultaneously extracting the input function and pharmacokinetic parameters of an active ingredient
    • 同时提取活性成分的输入功能和药代动力学参数的方法
    • US08571283B2
    • 2013-10-29
    • US13043969
    • 2011-03-09
    • Renaud MaroySegolene De Gavriloff
    • Renaud MaroySegolene De Gavriloff
    • G06K9/00
    • G06F19/704
    • This extraction method in a structure of a living organism from a measurement image of the kinetics of the active ingredient comprising a plurality of regions of interest inside each of which the kinetics of the active ingredient are measured, comprises the following steps: determining (30) a plurality of sets of kinetics, the determined sets of kinetics being different from each other and each determined set of kinetics including several measured kinetics; defining (32) at least one kinetic model, parameters of the defined kinetics model being formed by the parameters of the input function and the pharmacokinetic parameters; estimating (34) the input function and the pharmacokinetic parameters by resolving the kinetic model defined from the determined set of kinetics; and deducing (36) the final input function and the final pharmacokinetic parameters.
    • 来自活性成分的活性成分的动力学的测定图像的活性成分的结构的提取方法包括测定活性成分的动力学的各个感兴趣区域,包括以下步骤:确定(30) 多组动力学,确定的动力学集合彼此不同,并且每个确定的动力学集合包括几个测量的动力学; 定义(32)至少一个动力学模型,所定义的动力学模型的参数由输入函数的参数和药代动力学参数形成; 通过解决从确定的动力学集合定义的动力学模型来估计(34)输入函数和药代动力学参数; 并推导(36)最终输入函数和最终药代动力学参数。